Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059378 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| SCHEMBL143243 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| Pirfenidone SCHEMBL4708 | 0.80 | KDM4E (1.00) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| Pirfenidone SCHEMBL1006039 | 0.80 | KDM4E (1.00) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| SCHEMBL30827652 | 0.79 | CYP11B2 (0.47) | ALDH1A1CYP2A6CYP2E1CYP3A4EP300 | |
| SCHEMBL27250688 | 0.79 | KDM4E (0.56) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| SCHEMBL15713999 | 0.79 | EP300 (0.46) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| Pirfenidone SCHEMBL28532042 | 0.78 | KDM4E (0.96) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| Pirfenidone SCHEMBL22492268 | 0.78 | KDM4E (0.96) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD | |
| Pirfenidone SCHEMBL28079090 | 0.78 | KDM4E (0.96) | ALDH1A1HSD17B10KDM4ECYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866656-B1 | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS | MARGOLIN SOLOMON B (US) | 2007-04-25 | — | — | EP | claimed |
| EP-1261338-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY | CYMAR INC (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1069898-B1 | TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS | MARGOLIN SOLOMON B (US) | 2004-05-12 | — | — | EP | claimed |
| EP-0813409-B1 | TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS | MARGOLIN SOLOMON B (US) | 2004-05-06 | — | — | EP | claimed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1261338-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY | CYMAR INC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6956044-B1 | Compositions and methods for treatment of epilepsy | INTERMUNE, INC. | 2005-10-18 | — | — | US | disclosed |
| US-4052509-A | 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-4042699-A | 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1977-08-16 | — | — | US | disclosed |
| US-3974281-A | ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ALDH1A1 2109/4885HSD17B10 2478/4885KDM4E 616/4885 |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | ALDH1A1 2054/4885HSD17B10 2915/4885KDM4E 3381/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ALDH1A1 2109/4885HSD17B10 2478/4885KDM4E 616/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ALDH1A1 2109/4885HSD17B10 2478/4885KDM4E 616/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | ALDH1A1 358/4885HSD17B10 1369/4885KDM4E 1668/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ALDH1A1 2109/4885HSD17B10 2478/4885KDM4E 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.